Putting recent disappointments with solithromycin to one side, Cempra Inc. has reported positive Phase III data for its second product candidate, an old antibiotic called fusidic acid, which despite being available in Europe for decades has never received a US approval.
US FDA rejection of Cempra's solithromycin in December has pushed the novel antibiotic's approval back to 2018 at the earliest,...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)